Evidence map›Paper›PMID 39922931›Full record

ArticleScientific reports2025

SOCS2 inhibits the tumorigenesis of GISTs and increases the sensitivity of GISTs to imatinib by suppression of KIT activation.

Liangying Zhang, Kun Xiao, Shaoting Zhang, Sien Zhao, Zimei Liu, Ming Wang, Kaiyue Qin, Yuanyuan Yu, Shujing Li, Lijun Ma and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Liangying ZhangSchool of Basic Medical Sciences, Ningxia Medical University, Shengli Street 1160, Yinchuan, 750004, China.
Kun XiaoSchool of Basic Medical Sciences, Ningxia Medical University, Shengli Street 1160, Yinchuan, 750004, China.
Shaoting ZhangSchool of Basic Medical Sciences, Ningxia Medical University, Shengli Street 1160, Yinchuan, 750004, China.
Sien ZhaoSchool of Basic Medical Sciences, Ningxia Medical University, Shengli Street 1160, Yinchuan, 750004, China.
Zimei LiuDepartment of Oncology, Tongren Hospital, School of Medicine, Shanghai Jiao Tong University, Xianxia Road 1111, Shanghai, 200336, China.
Ming WangSchool of Basic Medical Sciences, Ningxia Medical University, Shengli Street 1160, Yinchuan, 750004, China.
Kaiyue QinSchool of Basic Medical Sciences, Ningxia Medical University, Shengli Street 1160, Yinchuan, 750004, China.
Yuanyuan YuThe General Hospital of Ningxia Medical University, Yinchuan, China.
Shujing LiThe General Hospital of Ningxia Medical University, Yinchuan, China.
Lijun MaDepartment of Oncology, Tongren Hospital, School of Medicine, Shanghai Jiao Tong University, Xianxia Road 1111, Shanghai, 200336, China. 732001971@shsmu.edu.cn.
Jianmin SunSchool of Basic Medical Sciences, Ningxia Medical University, Shengli Street 1160, Yinchuan, 750004, China. jianmin.sun@nxmu.edu.cn.

Funding

National Natural Science Foundation of China 82160521National Natural Science Foundation of China 82373141
6 · The paper itself

Abstract

The suppressors of cytokine signaling 2 (SOCS2) inhibits growth hormone receptor (GHR) signaling by negative feedback in the regulation of metabolism. In this study, we found that GHR upregulates SOCS2 expression, whereas KIT mutations, the key driver mutations of gastrointestinal stromal tumors (GISTs), inhibits SOCS2 expression in GISTs. Furthermore, SOCS2 associated and inhibited the activation of KIT mutations, but not wild-type KIT, in addition to its inhibition of GHR signaling, suggesting that KIT mutations may promote their activation by downregulation of SOCS2 expression. Accordingly, SOCS2 inhibited GIST cell survival and proliferation in vitro. In KIT

Indexed as

CarcinogenesisGastrointestinal Stromal TumorsImatinib MesylateProto-Oncogene Proteins c-kitSuppressor of Cytokine Signaling ProteinsAnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceMice, KnockoutMutationSignal TransductionAntineoplastic AgentsImatinib MesylateKIT protein, humanProto-Oncogene Proteins c-kitSOCS2 protein, humanSocs2 protein, mouseSuppressor of Cytokine Signaling ProteinsGISTsImatinibKITMutationSOCS2

Identifiers

PMID39922931
PMCPMC11807132

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.